ON Semiconductor (ON) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Vijay Rakesh maintained a Buy rating on ON Semiconductor (ON – Research Report) today and set a price target of $72.00. The company's shares closed today at $53.74.
Confident Investing Starts Here:
Rakesh covers the Technology sector, focusing on stocks such as Credo Technology Group Holding Ltd, Broadcom, and Nvidia. According to TipRanks, Rakesh has an average return of 15.9% and a 55.00% success rate on recommended stocks.
In addition to Mizuho Securities, ON Semiconductor also received a Buy from Wells Fargo's Joseph Quatrochi in a report issued on June 20. However, on June 18, B.Riley Financial maintained a Hold rating on ON Semiconductor (NASDAQ: ON).
The company has a one-year high of $80.08 and a one-year low of $31.04. Currently, ON Semiconductor has an average volume of 10.93M.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ON in relation to earlier this year. Earlier this month, Alan Campbell, a Director at ON sold 5,371.00 shares for a total of $274,780.36.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
28 minutes ago
- Business Insider
Why Is Plus Therapeutics Stock (PSTV) Up 100% Today?
Plus Therapeutics (PSTV) stock saw a huge rally on Wednesday as the clinical-stage pharmaceutical company received approval from the Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for REYOBIQ. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter This approval covers the use of REYOBIQ as a potential treatment for pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma. The company will conduct a clinical trial of this, with the U.S. Department of Defense providing a $3 million grant to fund the study. PSTV stock was up 103.69% in pre-market trading on Wednesday, following a 1.47% rally yesterday. However, the shares are down 83.74% year-to-date and have seen much volatility in 2025. This makes the stock a dangerous gambit not fit for risk-averse traders. Is Plus Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Plus Therapeutics is Strong Buy, based on three Buy and one Hold rating over the past three months. With that comes an average PSTV stock price target of $10, representing a potential 5,247.59% upside for the shares.
Business Insider
29 minutes ago
- Business Insider
Ord Minnett Sticks to Its Sell Rating for National Australia Bank Limited (NAUBF)
In a report released today, from Ord Minnett maintained a Sell rating on National Australia Bank Limited (NAUBF – Research Report), with a price target of A$33.00. The company's shares closed yesterday at $25.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Ord Minnett, National Australia Bank Limited also received a Sell from Citi's Thomas Strong in a report issued on June 16. However, on June 23, CLSA maintained a Hold rating on National Australia Bank Limited (Other OTC: NAUBF). The company has a one-year high of $28.75 and a one-year low of $17.30. Currently, National Australia Bank Limited has an average volume of 3,378.
Business Insider
29 minutes ago
- Business Insider
DBS Reaffirms Their Buy Rating on VNET Group, Inc. Sponsored ADR (VNET)
DBS analyst maintained a Buy rating on VNET Group, Inc. Sponsored ADR (VNET – Research Report) today and set a price target of $9.00. The company's shares closed yesterday at $6.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter VNET Group, Inc. Sponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $12.28, representing a 104.67% upside. In a report released on June 24, Bank of America Securities also maintained a Buy rating on the stock with a $11.30 price target. VNET market cap is currently $1.47B and has a P/E ratio of 99.32.
